series-a
Stage
2018
Founded
2
Investors
About
Asgard Therapeutics is a Swedish biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, developing gene therapies that reprogram tumor cells into antigen-presenting dendritic cells to trigger personalized immune responses against cancers.
Explore Asgard Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.